| Therapeutic | Tocilizumab |
| Target | IL6R |
| Heavy Chain | QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2004 |
| INN Year Recommended | 2004 |
| Companies Involved | Assistance Publique Hopitaux de Paris, Charite - Universitatsmedizin Berlin, Chugai Pharmaceutical, Hospital for Special Surgery, JW Pharmaceutical, Roche, University Hospital Inselspital, University Hospital, Osaka University Tubingen, University of Bern, University of Pittsburgh |
| Conditions Approved | Drug hypersensitivity, Giant cell arteritis, Giant lymph node hyperplasia, Juvenile rheumatoid arthritis, Rheumatoid arthritis, Vasculitis |
| Conditions Active | Adult-onset Still's disease, Osteoarthritis, Systemic scleroderma, Amyotrophic lateral sclerosis, Dermatomyositis, Familial Mediterranean fever, Polymyalgia rheumatica, Polymyositis, Pulmonary arterial hypertension, Schnitzler syndrome, Urogenital cancer |
| Conditions Discontinued | Chronic lymphocytic leukaemia, Ankylosing spondylitis, Crohn's disease, Multiple myeloma, Pancreatic cancer, Systemic lupus erythematosus |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
